Maker of the inhalable diabetes treatment, Afrezza, MannKind reclaimed 9 million shares of its common stock from Bank of America, the biopharmaceutical company said Monday.
The shares had been part of a stock lending agreement made with the lender in 2010.
It was used to help establish hedge positions by investors in MannKind when the firm offered senior convertible notes. Those shares, used as collateral for the debt held by note holders, were due Nov. 2015.
The Valencia firm said in a press release that MannKind had settled all payments and that the entire principal amount of senior notes were no longer outstanding. All payments and deliveries, per the agreement, were settled Aug. 17.
MannKind’s inhalable insulin treatment was approved by the FDA in the summer for 2014 after years of development. It then entered into a licensing agreement with Paris-based Sanofi for global distribution of the medication.
Ramp up of the production and distribution was less robust than expected for second quarter causing the firm’s stock to tumble from a high of $5.59 on July 23 to $3.53 at close of trading on Monday.
President and CEO of MannKind, Hakan Edstrom, urged patience with its investors, however. Efforts are still in the ramp up stage, including sales and marketing, and insurance reimbursements should be improving soon, he told investors.
Last week the company also announced it will begin trading on the Tel Avi Stock Exchange today, Oct. 28, in addition to the U.S.-based Nasdaq exchange.
